Derniers articles

Prevalence and Characteristics of Sleep Apnea in Intensive Care Unit Survivors After SARS-CoV-2 Pneumonia

AbstractBackground: Sleep apnea (SA) was reported as possibly exacerbating symptoms of COVID-19, a disease induced...

Posté par : Mme. Aurélia MEURISSE, Dr. Sophie PAGET-BAILLY
Nom de la revue : Nature and Science of Sleep

Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia

AbstractIntroduction: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Annals of Intensive Care

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Mme. Julie HENRIQUES, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancers (Basel)

Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer

AbstractBackground: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have changed the first-line...

Posté par : Dr. Sophie PAGET-BAILLY
Nom de la revue : Cochrane Database Syst Rev

An international tool to measure perceived stressors in intensive care units: the PS-ICU scale

AbstractBackground: The intensive care unit is increasingly recognized as a stressful environment for healthcare...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Ann Intensive Care .

Feasibility of a prehabilitation programme dedicated to older patients with cancer before complex medical-surgical procedures: the PROADAPT pilot study protocol

AbstractBackground: Ageing is associated with an increased prevalence of comorbidities and sarcopenia as well as a...

Posté par : Dr. Sophie PAGET-BAILLY
Nom de la revue : BMJ Open

Feasibility of health‑related quality of life (HRQoL) assessment for cancer patients using electronic patient‑reported outcome (ePRO) in daily clinical practice

AbstractIntroduction - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical...

Posté par : , Mr. Antoine FALCOZ, Mme. Joëlle FRITZSCH, , , Dr. Sophie PAGET-BAILLY
Nom de la revue : Quality of Life Research

11 November, 2020

Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients

AbstractBackground: Randomized controlled trials (RCTs) represent the best evidence in oncology research....

Posté par : Mr. Antoine FALCOZ, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY
Nom de la revue : Neurooncol Pract

Impact of routine assessment of health-related quality of life coupled with therapeutic information on compliance with endocrine therapy in patients with non-metastatic breast cancer: protocol for a randomized controlled trial

Background: Despite its proven efficacy in reducing recurrence and improving survival, adherence to endocrine...

Posté par : Dr. Sophie PAGET-BAILLY
Nom de la revue : Trials

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

AbstractBackground: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : Lancet

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...

Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

ABSTRACTBackground: Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : The Breast

3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

ABSTRACTPurpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Journal of Clinical Oncology

Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence

PurposeThe aim of this study was to determine the prevalence of adherence to adjuvant hormonal therapy (AHT) and to...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Breast Cancer Research and Treatment

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study

AbstractBackgroundWe studied the relationship between intermediate criteria and overall survival (OS) in metastatic...

Posté par : Dr. Sophie PAGET-BAILLY, Pr. Franck BONNETAIN
Nom de la revue : Clinical Colorectal Cancer

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

AbstractBackground: Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : Breast Cancer Research

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort

Abstract Aim: Adjuvant clinical trials in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer...

Posté par : Mme. Julie HENRIQUES, Dr. Sophie PAGET-BAILLY
Nom de la revue : European Journal of Cancer

Évaluation de la qualité de vie relative à la santé suite au diagnostic de cancer

La mesure de la qualité de vie relative à la santé des personnes traitées pour un cancer se développe. Ce nouvel...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Mme. Joëlle FRITZSCH,
Nom de la revue : La revue de l'infirmière

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics

Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma

Docetaxel, cisplatin, and 5-fluorouracil (DCF) significantly improved overall survival in metastatic gastroesophageal...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancer Medecine

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma

Background: Even though the perioperative chemotherapy improves the overall survival (OS) compared to surgery alone in...

Posté par : Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : European Journal of Surgical Oncology

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

BACKGROUND:A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using...

Posté par : Pr. Franck BONNETAIN, , Dr. Sophie PAGET-BAILLY
Nom de la revue : PlosOne

Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.

AbstractOverall survival (OS) has been considered as the most relevant primary endpoint but trials using OS often...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY
Nom de la revue : Expert Review of Anticancer Therapy